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Introduction
According to the 2014 Centers for
Disease Control (CDC) 9.3% of the United
States Population have diabetes (National
diabetes statistics report, “2014, p.1). One
of the complications of diabetes is
gastroparesis. Gastroparesis is “a delay in
the emptying of ingested food in the
absence of mechanical obstruction of the
stomach or duodenum ‘’ (Koch & CallesEscandon, 2015, p. 40). Mortality in the
diabetic patient with gastroparesis is higher
than the diabetic patient without
gastroparesis (Koch & Calles-Escandon,
2015). Patients with either type 1 diabetes
(T1DM) or type 2 diabetes (T2DM) may
experience he clinical symptoms of early
satiety, prolonged fullness, nausea, and
vomiting, and have difficulties with
management of blood glucose levels,
nutritional issues, and other drug
absorption issues (Koch & Calles-Escandon,
2015). Health care providers may see
patients in a variety of settings, with and
without known diagnosis of gastroparesis
and must be aware of the symptoms, the
potential diagnosis, the appropriate
testing, and the options for treatment.
Advances in the treatment of gastroparesis
surround the increased understanding of
the pathophysiology behind gastroparesis.

Signs & symptoms
•
•
•
•
•
•
•
•
•

nausea
early satiety
bloating
abdominal or epigastric pain
impaired glycemic control
malnutrition
poor drug absorption
poor quality of life
frequent hospitalizations
(Shin & Camilleri, 2013)

Pathophysiology
The normal activity in gastric motility involves three areas of action.
•
The fundus, which relaxes with a volume of food ingested and
requires an intact vagus nerve and enteric neurons (Koch &
Calles-Escandon, 2015)
•
The corpus and antrum, which produce recurrent waves at a
frequency of 3 cycles per minute, turning digested food solids
into finer material called chyme. These peristaltic waves are
controlled by gastric pacemaker cells call Interstitial cells of
cajal (ICCs) (Koch & Calles-Escandon, 2015).
•
The emptying of chyme through the pylorus into the
duodenum. The pylorus regulates the volume and particle
size of chyme and is affected by catecholamine and peptide
releases (Koch & Calles-Escandon, 2015).

Significance of Pathophysiology on
Gastroparesis
•
•
•
•
•
•
•
•
•
•
•
•

Normal gastric neuromuscular function (Koch &
Calles-Escandon, 2015)

•

There are several alterations suspected in gastroparesis.
•
The most common abnormality is loss or depletion of ICCs . ICCs
regulate contractility and impaired ICCs results in gastric
dysrhythmias (Farrugia, 2015).
•
Damage to the vagus nerve innervation to the stomach, may lead to
motor abnormalities and abnormal relaxation of the pylorus
(Farrugia ,2015).
•
Evidence has shown smooth muscle degeneration and end stage
evidence may include fibrosis with eosinophilic inclusion bodies
(Farrugia, 2015).
•
Loss of neurotransmitters, such as neuronal nitric oxide synthase
(nNOS) have been seen and are thought to be reversible (Farrugia,
2015). Nitregic neuron loss and ICC loss is thought to account of the
poor fundic relaxation and decreased gastric capacity that is seen in
gastroparesis (Koch & Calles-Escandon, 2015).
•
Fibroblast-like cells (FLCs), similar to ICCs are involved in
neurotransmission, and may be decreased in gastroparesis
(Farrugia, 2015).
•
Alterations in the balance of pro-inflammatory M1 macrophages
and anti-inflammatory M2 macrophages of the stomach wall muscle
are suspected to become disrupted in gastroparesis (Farrugia, 2015).
M1 macrophages are associated with the development of delayed
gastric emptying (Farrugia, 2015).

•

•

•
•

Understanding the various potential alterations that lead to gastroparesis can affect the
treatment or management of symptoms and mode of testing.
The gold standard test used for evaluation of gastric emptying is the gastric emptying
study (GES), although associations are weak between abnormal results and patient
symptoms due to various pathophysiology mechanisms (Shin & Camilleri, 2013).
Alternative methods of testing exist (Shin & Camilleri, 2013).
Assessment of symptoms and other factors, such as age, sex, comorbidities, patient
preference, and test availability should contribute to the decision of mode of testing
(Shin & Camilleri, 2013).
Treatments are palliative and empiric in focus and not curative (Pasricha, 2015).
Common treatments aimed at increasing gastric emptying (Pasricha, 2015).
Nutritional support, fluid and electrolyte restoration, glycemic control, (Acosta &
Camilleri, 2015) .
Six or more meals or snacks a day are needed to meet nutritional needs and include
restricted fat and fiber intake: tolerance is improved with liquids or ground foods (Rees
Parish, 2015).
Prokinetic medication help gastric emptying by “restoring the synchronicity between
delivery of food and hormone and peptide release, but it does not target the underlying
defects” (Farrugia, 2015, p. 6).
Metoclopramide, a dopamine 2 receptor agonist, is the only approved prokinetic
medication in the United States; use is limited to less than 13 weeks of treatment
(Acosta & Camilleri, 2015).
Domperidone is another dopamine 2 agonist, but use is considered investigational
(Acosta & Camilleri, 2015).
Antiemetic medications are often utilized for control of nausea, but one study suggests
that antiemetics show modest benefit in comparison to non- use (Hasler, 2015).
Opiate analgesia are often used but use could exacerbate nausea and vomiting and also
slow gastric emptying (Hasler, 2015).
Hyperglycemia treatment with insulin, may improve and normalize ICCs (Koch & CallesEscandon, 2015).
Gastric pacemakers provide gastric electrical stimulation aimed at controlling nausea
and improving vagal function when other therapies failed ; more understanding of
gastric mapping is needed (Sarosiek et al., 2015).
A jejunostomy tube may be needed for patients experiencing gastroparesis in order to
maintain hydration, nutrition, and glycemic control.
Newer agents are being studied and developed by targeting different pathways and
include serotonin receptor agonists, ghrelin agonists (Acosta & Camilleri, 2015).

Neuromuscular function in gastroparesis (Koch & Calles-Escandon, 2015)

Implications for Nursing
Care
Having an understanding of the diagnosis of
gastroparesis, symptom recognition, and understanding
of the behind it, is important for nurses in a variety of
roles. Diabetic patients are often afflicted with
gastroparesis. Gastroparesis affects glycemic control
and lack of glycemic control can lead to gastroparesis
(Koch & Calles-Escandon, 2015). Nurses can have
pivotal role in diabetic education affecting glycemic
control. Dietary education in tandem with dietary
professionals, can also provide symptomatic relief from
those suffering from gastroparesis. Knowledge of
gastroparesis and medication therapy can also benefit
patients through nurse request for appropriate
medication, and patient education of those drugs.
Advance practice nurse knowledge of gastroparesis, can
lead to improvement is patient assessments, testing,
symptom management, awareness of potential
electrolyte imbalance, and patient nutrition and
diabetes management. Since the symptoms of
gastroparesis lead to frequent medical visits and
hospitalization, sensitivity to patient quality of life and
screening for symptoms of depression may be
important.

Conclusion
Diabetic patients often experience
gastroparesis. A cure for gastroparesis is not
present. Research and better understanding of the
pathophysiology of gastric motility and function is
needed to further advance the treatment of
gastroparesis and its symptoms. Until then,
knowledge of the prevalence of gastroparesis in
diabetics, symptom awareness, testing, and
appropriate choosing of available medical therapies
is important. Support of the patient in nutrition and
glycemic management is needed, as well as support
of the patient’s emotional well being.
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